Galapagos NV (GLPG.AS)

26,98 -0,36 (-1,32%) Börsenschluss: 05:35PM CEST

Galapagos NV

Generaal De Wittelaan L11 A3
Mechelen 2800
Belgium
32 1 534 29 00
https://www.glpg.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 1.123

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Dr. Paulus A. Stoffels M.D., Ph.D.	CEO, Chairman, Interim Head of R&D	1,26M	N/A	1962
Mr. Thad Huston	Executive VP, CFO & COO	N/A	N/A	1971
Ms. Sofie Van Gijsel	Head of Investor Relations	N/A	N/A	N/A
Ms. Valeria Cnossen	Executive VP & General Counsel	N/A	N/A	1974
Marieke Vermeersch	Head of Corporate Communication	N/A	N/A	N/A
Ms. Annelies Missotten	Executive VP & Chief Human Resources Officer	N/A	N/A	1973
Ms. Ellen Van Der Aar	Head of Development	N/A	N/A	N/A
Mr. Philippe Alen M.B.A., Ph.D., Pharm.D.	Senior VP & Head of Business Development	N/A	N/A	N/A
Mr. Dirk De Naeyer	Head of Development Operations	N/A	N/A	N/A
Ms. Alice Dietrich	Head of Medical Affairs	N/A	N/A	N/A

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in EUR.

Beschreibung

Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc.; and AbbVie S.à r.l. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.

Corporate Governance

Galapagos NVs ISS Governance QualityScore, Stand 1. Mai 2024, lautet 7. Die grundlegenden Scores sind Audit: 6, Vorstand: 4, Shareholderrechte: 4, Kompensation: 10.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.